VRNA Verona Pharma
- 21.600
- +2.070+10.60%
- 21.848
- +0.248+1.15%
Verona Pharma News
Earnings Call Summary | Verona Pharma(VRNA.US) Q2 2024 Earnings Conference
Verona Pharma | 10-Q: Quarterly report
Verona Pharma GAAP EPS of -$0.11 Beats by $0.10
Verona Pharma CEO: Ohtuvayre (Ensifentrine) Now Available in the U.S. for Maintenance Treatment of Chronic Obstructive Pulmonary Disease in Adults >VRNA
Verona Pharma 2Q Loss/Shr 11c Vs. Loss 1c >VRNA
Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
European Equities Traded in the US as American Depositary Receipts Plunge in Monday Trading
Verona Pharma Plc's (NASDAQ:VRNA) Path To Profitability
European Equities Traded in the US as American Depositary Receipts Sharply Down in Friday Trading
Top 3 Health Care Stocks You May Want To Dump This Quarter
Verona Pharma to Present at 44th Annual Canaccord Growth Conference
European Equities Traded in the US as American Depositary Receipts Trend Slightly in Thursday Trading
Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update
Verona Pharma Is Maintained at Buy by Canaccord Genuity
Express News | Verona Pharma PLC : Canaccord Genuity Raises Target Price to $37 From $35
Analysts Have Conflicting Sentiments on These Healthcare Companies: Astellas Pharma (OtherALPMF) and Verona Pharma (VRNA)
CCORF Maintains Verona Pharma(VRNA.US) With Buy Rating, Raises Target Price to $37
European Equities Traded in the US as American Depositary Receipts Trend Lower Friday; Set to End Week Down 4%
European Equities Traded in the US as American Depositary Receipts Trend Lower Thursday
Analysis
Price Target
No Data
